Tradestie Institutional Equity Comparison Engine

RYOJ vs NSRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NSRX Overall Edge

NSRX Captures Institutional Edge (1โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nasus Pharma Ltd. (NSRX) driven by superior Growth & Margin while RYOJ counters with relative strength in Momentum & Technical. Fundamentally, RYOJ trades at N/M Forward P/E with -8.1% operating margin (-34.3% YoY revenue) versus NSRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RYOJ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NSRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RYOJ N/M vs NSRX N/M Fwd P/E
Growth & Margin Winner NSRX
Op Margin -8.1% vs 0.0% ยท YoY -34.3% vs +0.0%
Momentum & Technical Winner RYOJ
1Y -49.0% vs -66.2% ยท 52W Pos 10% vs 8%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RYOJ NASDAQ
rYojbaba Co., Ltd. Common Shares
Services-Management Consulting Services
$2.23
-0.89% 1D
Market Cap $26.0M
1M Return -11.51%
1Y Return -48.97%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 23.0 Fund 50.0 Flow 50.0 Mom 64.0
NSRX NYSE American
Nasus Pharma Ltd.
Pharmaceutical Preparations
$2.55
-5.56% 1D
Market Cap $31.6M
1M Return -16.67%
1Y Return -66.23%
Forward P/E N/M
Unified AI Score
45.4 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RYOJ -48.97% NSRX -66.23% Spread: +17.43 pp (RYOJ Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RYOJ TTM Op. Margin: -8.1% NSRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RYOJ vs NSRX. Trailing 12-month operating profitability (RYOJ -8.1% vs NSRX 0.0%) and valuation multiples (RYOJ N/M vs NSRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RYOJ (3) vs NSRX (4)
Institutional Metric RYOJ NSRX Criterion Row Winner
Market Capitalization Scale $26.0M $31.6M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -34.3% +0.0% Higher Growth NSRX
Operating Margin (TTM) Profitability -8.1% 0.0% Higher Margin NSRX
Net Profit Margin Profitability 1.3% 0.0% Higher Margin RYOJ
Return on Equity (ROE) Capital Efficiency 2.8% -316.0% Higher ROE RYOJ
52-Week Range Position Momentum 10% ($2โ€“$8) 8% ($2โ€“$10) Stronger Trend RYOJ
Beta / 30D Volatility Risk Regime 1.68ฮฒ ยท 92% Vol 1.00ฮฒ ยท 69% Vol Lower Realized Risk NSRX
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite NSRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RYOJ vs NSRX Buy Guide
RYOJ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RYOJ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NSRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NSRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RYOJ nor NSRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.